retatrutide triple agonist clinical trial There's a new name in the GLP conversation — and it's worth paying attention to. is a triple-agonist therapy that targets GLP-1, GIP, and glucagon receptors simultaneously. In trials, it retatrutide triple agonist glp-1 gip
Pay in 4 interest-free payments of $7.24 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9





















